Desperately seeking…Models to find the right partner and the best use for checkpoint inhibitors

Research output: Contribution to journalEditorial


Immune checkpoint inhibitors have shown unprecedented clinical activity in a variety of cancer types, but only in a fraction of patients. Promising in vivo synergies have been demonstrated between checkpoint inhibitors and other drugs and/or chemotherapy or radiotherapy, and effective models are now needed to select the best combinatorial regimen and disease setting.

Original languageEnglish
Pages (from-to)139-140
Number of pages2
JournalBritish Journal of Cancer
Issue number2
Publication statusPublished - Jan 22 2019


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this